[A16-01] Pertuzumab - Addendum to Commission A15-34
Last updated 18.02.2016
Commission awarded on 14.01.2016 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-41||Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A15-34||Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|